1
|
Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation.
|
Hypertension
|
2013
|
2.82
|
2
|
The assessment of endothelial function: from research into clinical practice.
|
Circulation
|
2012
|
2.68
|
3
|
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension.
|
J Hypertens
|
2005
|
2.46
|
4
|
Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension.
|
J Hypertens
|
2005
|
2.12
|
5
|
Relationship between wave reflection and renal damage in hypertensive patients: a retrospective analysis.
|
J Hypertens
|
2013
|
1.98
|
6
|
Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine.
|
J Hypertens
|
2015
|
1.97
|
7
|
Endothelial dysfunction as a target for prevention of cardiovascular disease.
|
Diabetes Care
|
2009
|
1.91
|
8
|
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
|
Eur Heart J
|
2012
|
1.91
|
9
|
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.
|
Br J Clin Pharmacol
|
2009
|
1.81
|
10
|
Is oxidative stress a therapeutic target in cardiovascular disease?
|
Eur Heart J
|
2010
|
1.67
|
11
|
Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study.
|
J Hypertens
|
2012
|
1.62
|
12
|
Endothelium-dependent contractions in hypertension.
|
Br J Pharmacol
|
2005
|
1.59
|
13
|
Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women.
|
J Hypertens
|
2003
|
1.49
|
14
|
Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men.
|
Am J Hypertens
|
2005
|
1.49
|
15
|
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
|
Blood Press
|
2005
|
1.49
|
16
|
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients.
|
Circulation
|
2009
|
1.49
|
17
|
Different effect of antihypertensive drugs on conduit artery endothelial function.
|
Hypertension
|
2003
|
1.48
|
18
|
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.
|
JAMA
|
2004
|
1.40
|
19
|
Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up.
|
Nephrol Dial Transplant
|
2011
|
1.40
|
20
|
Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway.
|
Hypertension
|
2008
|
1.39
|
21
|
Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients.
|
Am J Hypertens
|
2007
|
1.36
|
22
|
The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients.
|
J Am Coll Cardiol
|
2003
|
1.33
|
23
|
Endothelium-dependent contractions and endothelial dysfunction in human hypertension.
|
Br J Pharmacol
|
2009
|
1.27
|
24
|
The eye and the heart.
|
Eur Heart J
|
2013
|
1.18
|
25
|
Endothelial dysfunction and oxidative stress in chronic renal failure.
|
J Nephrol
|
2004
|
1.17
|
26
|
Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients.
|
J Am Coll Cardiol
|
2011
|
1.16
|
27
|
Hydrogen sulphide: novel opportunity for drug discovery.
|
Med Res Rev
|
2010
|
1.11
|
28
|
Sympathetic regulation of vascular function in health and disease.
|
Front Physiol
|
2012
|
1.07
|
29
|
Hypertension and endothelial dysfunction: therapeutic approach.
|
Curr Vasc Pharmacol
|
2012
|
1.06
|
30
|
Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis.
|
Free Radic Biol Med
|
2010
|
1.02
|
31
|
Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice.
|
Hypertension
|
2006
|
1.02
|
32
|
Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension.
|
Hypertension
|
2010
|
0.97
|
33
|
Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin II.
|
Int J Hypertens
|
2011
|
0.96
|
34
|
Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients.
|
J Hypertens
|
2007
|
0.96
|
35
|
Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids.
|
Hypertension
|
2009
|
0.96
|
36
|
Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma.
|
J Clin Endocrinol Metab
|
2006
|
0.95
|
37
|
Non-invasive diagnostic tools for investigating endothelial dysfunction.
|
Curr Pharm Des
|
2008
|
0.94
|
38
|
Anthropometric and dietary determinants of blood pressure in over 7000 Mediterranean women: the European Prospective Investigation into Cancer and Nutrition-Florence cohort.
|
J Hypertens
|
2008
|
0.93
|
39
|
Intima media thickness, pulse wave velocity, and flow mediated dilation.
|
Cardiovasc Ultrasound
|
2014
|
0.92
|
40
|
Poor sleep quality and resistant hypertension.
|
Sleep Med
|
2013
|
0.91
|
41
|
Renal vasodilating capacity and endothelial function are impaired in patients with obstructive sleep apnea syndrome and no traditional cardiovascular risk factors.
|
J Hypertens
|
2013
|
0.90
|
42
|
Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.
|
Curr Med Res Opin
|
2010
|
0.90
|
43
|
Effects of antihypertensive treatment on endothelial function.
|
Curr Hypertens Rep
|
2011
|
0.89
|
44
|
Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress.
|
J Pharmacol Exp Ther
|
2004
|
0.88
|
45
|
Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus.
|
Hypertension
|
2007
|
0.88
|
46
|
Adipocytokine levels mark endothelial function in normotensive individuals.
|
Cardiovasc Diabetol
|
2012
|
0.88
|
47
|
Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy.
|
J Clin Endocrinol Metab
|
2006
|
0.88
|
48
|
Local carotid stiffness and intima-media thickness assessment by a novel ultrasound-based system in essential hypertension.
|
Atherosclerosis
|
2012
|
0.87
|
49
|
Investigation of skin vasoreactivity and blood flow oscillations in hypertensive patients: effect of short-term antihypertensive treatment.
|
J Hypertens
|
2011
|
0.87
|
50
|
Human endothelial dysfunction: EDCFs.
|
Pflugers Arch
|
2010
|
0.86
|
51
|
Endothelial dysfunction in essential hypertension: clinical implications.
|
J Hypertens
|
2002
|
0.86
|
52
|
Reversibility of the endothelial dysfunction after CPAP therapy in OSAS patients.
|
Int J Cardiol
|
2011
|
0.86
|
53
|
Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D.
|
J Renin Angiotensin Aldosterone Syst
|
2013
|
0.86
|
54
|
Inflammation and not cardiovascular risk factors is associated with short leukocyte telomere length in 13- to 16-year-old adolescents.
|
Arterioscler Thromb Vasc Biol
|
2012
|
0.86
|
55
|
The ageing endothelium, cardiovascular risk and disease in man.
|
Exp Physiol
|
2008
|
0.85
|
56
|
Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure.
|
Am J Cardiol
|
2010
|
0.85
|
57
|
Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension.
|
Curr Hypertens Rep
|
2009
|
0.84
|
58
|
Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension?
|
J Nephrol
|
2002
|
0.84
|
59
|
Predictive role of renal resistive index for clinical outcome after revascularization in hypertensive patients with atherosclerotic renal artery stenosis: a monocentric observational study.
|
Cardiovasc Ultrasound
|
2014
|
0.84
|
60
|
Functional and structural alterations of large arteries: methodological issues.
|
Curr Pharm Des
|
2013
|
0.83
|
61
|
Phosphodiesterase 5 inhibition in essential hypertension.
|
Curr Hypertens Rep
|
2008
|
0.83
|
62
|
Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.
|
Mol Med
|
2009
|
0.83
|
63
|
Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?
|
Eur Heart J
|
2012
|
0.83
|
64
|
Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients.
|
Am J Clin Nutr
|
2012
|
0.82
|
65
|
Inducible nitric oxide synthase is involved in endothelial dysfunction of mesenteric small arteries from hypothyroid rats.
|
Endocrinology
|
2008
|
0.82
|
66
|
Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients.
|
Eur Heart J
|
2012
|
0.82
|
67
|
Coronary flow reserve in idiopathic dilated cardiomyopathy: relation with left ventricular wall stress, natriuretic peptides, and endothelial dysfunction.
|
J Am Soc Echocardiogr
|
2009
|
0.82
|
68
|
Chronic treatment with long-acting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension.
|
Hypertension
|
2006
|
0.82
|
69
|
Neuroendocrine markers and psychological features in patients with irritable bowel syndrome.
|
Int J Colorectal Dis
|
2013
|
0.82
|
70
|
Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study).
|
Trials
|
2013
|
0.82
|
71
|
Peripheral wave reflection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome.
|
J Hypertens
|
2008
|
0.81
|
72
|
The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment.
|
J Clin Endocrinol Metab
|
2009
|
0.80
|
73
|
Endothelium-dependent vasodilation and carotid artery wall remodeling in athletes and sedentary subjects.
|
Atherosclerosis
|
2005
|
0.80
|
74
|
Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
|
Clin Drug Investig
|
2010
|
0.80
|
75
|
Enhanced proatherogenic inflammation after recombinant human TSH administration in patients monitored for thyroid cancer remnant.
|
Clin Endocrinol (Oxf)
|
2008
|
0.80
|
76
|
Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment.
|
PLoS One
|
2013
|
0.80
|
77
|
Skin vasodilator effect of exogenous urotensin-II in hypertensives not exposed to antihypertensive medication.
|
Blood Press
|
2008
|
0.79
|
78
|
Association between short leukocyte telomere length, endotoxemia, and severe periodontitis in people with diabetes: a cross-sectional survey.
|
Diabetes Care
|
2014
|
0.79
|
79
|
Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients.
|
Am J Hypertens
|
2009
|
0.79
|
80
|
Psychological predictors of the antihypertensive effects of music-guided slow breathing.
|
J Hypertens
|
2010
|
0.79
|
81
|
Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition.
|
Eur Heart J
|
2011
|
0.79
|
82
|
Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease.
|
Biomed Pharmacother
|
2009
|
0.78
|
83
|
Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients.
|
Hypertension
|
2007
|
0.78
|
84
|
Evaluation of microvascular structure in humans: a 'state-of-the-art' document of the Working Group on Macrovascular and Microvascular Alterations of the Italian Society of Arterial Hypertension.
|
J Hypertens
|
2014
|
0.78
|
85
|
Soy protein diet improves endothelial dysfunction in renal transplant patients.
|
Nephrol Dial Transplant
|
2006
|
0.78
|
86
|
Evaluation of endothelial function by flow mediated dilation: methodological issues and clinical importance.
|
High Blood Press Cardiovasc Prev
|
2014
|
0.78
|
87
|
Microvascular endothelial dysfunction in obesity and hypertension.
|
Curr Pharm Des
|
2013
|
0.77
|
88
|
Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin.
|
Hypertension
|
2003
|
0.77
|
89
|
Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1.
|
Br J Pharmacol
|
2013
|
0.77
|
90
|
Hope for the future: early recognition of increased cardiovascular risk in children and how to deal with it.
|
Eur J Cardiovasc Prev Rehabil
|
2009
|
0.77
|
91
|
Vascular reactivity in patients with undifferentiated connective tissue diseases.
|
Atherosclerosis
|
2008
|
0.77
|
92
|
Birth weight and arterial hypertension.
|
Curr Opin Cardiol
|
2015
|
0.77
|
93
|
P2X7 receptor polymorphisms do not influence endothelial function and vascular tone in neo-diagnosed, treatment-naive essential hypertensive patients.
|
J Hypertens
|
2013
|
0.77
|
94
|
Phosphodiesterase 5 inhibition to treat essential hypertension: is this the beginning of the story?
|
Hypertension
|
2006
|
0.76
|
95
|
Hypertension in special populations: athletes.
|
Future Cardiol
|
2011
|
0.76
|
96
|
Exogenous ghrelin on nitric oxide-endothelin 1 imbalance in metabolic syndrome: can we kill 2 birds with 1 stone?
|
Hypertension
|
2009
|
0.76
|
97
|
Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
|
J Androl
|
2004
|
0.76
|
98
|
Human Ghrelin: A Gastric Hormone with Cardiovascular Properties.
|
Curr Pharm Des
|
2015
|
0.76
|
99
|
Sporadic or familial head neck paragangliomas enrolled in a single center: clinical presentation and genotype/phenotype correlations.
|
Head Neck
|
2012
|
0.76
|
100
|
Endothelial function in hypertension: role of gender.
|
J Hypertens Suppl
|
2002
|
0.76
|
101
|
At the beginning of stiffening: endothelial dysfunction meets "pulsology".
|
Hypertension
|
2006
|
0.75
|
102
|
Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
|
J Hypertens
|
2012
|
0.75
|
103
|
How to evaluate microvascular organ damage in hypertension: assessment of endothelial function.
|
High Blood Press Cardiovasc Prev
|
2011
|
0.75
|
104
|
Angiotensin II as the link between nitric oxide and neuroadrenergic function.
|
J Hypertens
|
2005
|
0.75
|
105
|
Response to Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction?
|
Hypertension
|
2013
|
0.75
|
106
|
Carotid and aortic stiffness in essential hypertension and their relation with target organ damage: the CATOD study.
|
J Hypertens
|
2016
|
0.75
|
107
|
Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas.
|
Clin Nucl Med
|
2014
|
0.75
|
108
|
Long life to olive oil and wine! Long life with olive oil and wine?
|
J Hypertens
|
2008
|
0.75
|
109
|
Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D.
|
J Hypertens
|
2016
|
0.75
|
110
|
Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants.
|
Curr Pharm Des
|
2014
|
0.75
|
111
|
Clinical management of drug-induced hypertension: 2013 Practical Recommendations of the Italian Society of Hypertension (SIIA).
|
High Blood Press Cardiovasc Prev
|
2014
|
0.75
|
112
|
Understanding the relationship between lung function and cardiovascular phenotypes in the young: opportunity for a better cardiovascular risk prevention in adulthood?
|
J Hypertens
|
2017
|
0.75
|
113
|
Multigroup confirmatory factor analysis of U.S. and Italian children's performance on the PASS theory of intelligence as measured by the Cognitive Assessment System.
|
Psychol Assess
|
2012
|
0.75
|
114
|
Adrenal hormones and the heart.
|
Eur Heart J
|
2015
|
0.75
|
115
|
[The HEAAL study].
|
G Ital Cardiol (Rome)
|
2010
|
0.75
|
116
|
Blood pressure and vascular alterations with growth in childhood.
|
Curr Pharm Des
|
2011
|
0.75
|
117
|
Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study.
|
J Hypertens
|
2016
|
0.75
|
118
|
[The Symplicity HTN-3 study].
|
G Ital Cardiol (Rome)
|
2014
|
0.75
|
119
|
Device-based therapies for resistant hypertension.
|
Curr Pharm Des
|
2013
|
0.75
|
120
|
Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects.
|
J Hypertens
|
2006
|
0.75
|
121
|
[Resistant hypertension: a case report].
|
Recenti Prog Med
|
2010
|
0.75
|
122
|
Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
|
Eur Heart J
|
2017
|
0.75
|
123
|
Endothelial Dysfunction in Resistance Arteries of Hypertensive Humans: Old and New Conspirators.
|
J Cardiovasc Pharmacol
|
2016
|
0.75
|